Markets:

Overview

News

Currencies

International

Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

25.82 +4.68 (+22.14%)

Official Closing Price Updated: 4:15 PM EST, Feb 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Why Roivant Sciences Stock Was Slipping on Monday ↗

August 11, 2025

The distinctive biotech wasn't a sector favorite as the trading week began.

Via The Motley Fool

Beyond the Headlines: A Look at Today's Key Corporate Earnings Reports

August 11, 2025

Today, August 11, 2025, marks a significant day for investors looking beyond the typical S&P 500 giants, as a diverse array of companies across various sectors unveiled their latest quarterly earnings....

Via MarketMinute

Topics Economy Stocks

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

August 11, 2025

From Roivant Sciences

Via GlobeNewswire

A Glimpse of Roivant Sciences's Earnings Potential ↗

August 08, 2025

Via Benzinga

What Does the Market Think About Roivant Sciences? ↗

July 23, 2025

Via Benzinga

Earnings Scheduled For August 11, 2025 ↗

August 11, 2025

Via Benzinga

Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

July 28, 2025

From Roivant Sciences

Via GlobeNewswire

Peering Into Roivant Sciences's Recent Short Interest ↗

June 25, 2025

Via Benzinga

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

June 16, 2025

From Pulmovant, Inc.

Via GlobeNewswire

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis

June 09, 2025

From Roivant Sciences

Via GlobeNewswire

Roivant Sciences's Earnings Outlook ↗

May 28, 2025

Via Benzinga

Roivant Sciences Q3 Earnings Assessment ↗

February 10, 2025

Via Benzinga

Stocks Edge Higher After Court Stifles Trump Tariffs, Nvidia Rallies To 3-Month Highs, Bitcoin Dips Below $107K: What's Driving Markets Thursday? ↗

May 29, 2025

Wall Street hovered slightly higher by midday Thursday, giving up a chunk of strong overnight gains in futures markets that were triggered by a federal court ruling suspending a large portion of...

Via Benzinga

Topics Government

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update

May 29, 2025

From Roivant Sciences

Via GlobeNewswire

Earnings Scheduled For May 29, 2025 ↗

May 29, 2025

Via Benzinga

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025

May 15, 2025

From Roivant Sciences

Via GlobeNewswire

Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift ↗

April 21, 2025

The company is getting a new chief executive and a new chief financial officer amid sweeping changes.

Via Investor's Business Daily

Topics Government

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

April 21, 2025

From Roivant Sciences

Via GlobeNewswire

Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data ↗

March 19, 2025

Immunovant's batoclimab showed positive Phase 3 results in MG but won't be pursued for approval as the company shifts focus to its lead asset, IMVT-1402.

Via Benzinga

Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled. ↗

March 19, 2025

The companies reported positive results for their lead asset in patients with two rare diseases.

Via Investor's Business Daily

Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

March 19, 2025

From Roivant Sciences

Via GlobeNewswire

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

March 18, 2025

From Roivant Sciences

Via GlobeNewswire

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

March 03, 2025

From Arbutus Biopharma Corporation

Via GlobeNewswire

Tech Stocks Surge, Steelmakers Jump On Trump's 25% Tariffs, Copper Hits 9-Month Highs: What's Driving Markets Monday? ↗

February 10, 2025

Wall Street bounced back on Monday, recovering from Friday's robust decline fueled by tariff concerns, as investors remained focused on strong earnings from the fourth-quarter reporting season while...

Via Benzinga

Topics Government World Trade

Roivant Sciences Tops Q3 Expectations ↗

February 10, 2025

Roivant Sciences posted earnings that exceeded expectations, with substantial progress in its diversified drug pipeline.

Via The Motley Fool

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update

February 10, 2025

From Roivant Sciences

Via GlobeNewswire

Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care

February 03, 2025

Zest is initially focused on treating the millions of Americans with inflammatory skin diseases who are currently overprescribed expensive biologics

From Roivant Sciences

Via GlobeNewswire

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025

January 29, 2025

From Roivant Sciences

Via GlobeNewswire

Earnings Scheduled For February 10, 2025 ↗

February 10, 2025

Via Benzinga

Trump Index: 6 Companies Linked to Trump’s Cabinet Worth Watching

January 28, 2025

President Trump's cabinet is comprised of millionaires, billionaires and leaders in business who founded or led public companies. Here's the TRUMP index stocks.

Via MarketBeat

Topics Government

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.